GRAIL
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for ...
Latest News
6 days ago · seekingalpha.com
GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference TranscriptGRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST Company Participants Aaron Freidin - CFO & Head of Corporate Development Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning.
7 days ago · 247wallst.com
Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029Congress finally cleared a path for Medicare to cover a multi-cancer blood test, but a quirk in the fine print moves the goalposts every year. For one 70-year-old patient, the clock may never line up, and her doctor's next suggestion carries hidden costs.
12 days ago · zacks.com
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales GrowthGRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
12 days ago · seekingalpha.com
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call TranscriptGRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
12 days ago · marketbeat.com
What GRAIL (GRAL) Said on Its Q3 Earnings CallGRAIL NASDAQ: GRAL reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027.
12 days ago · prnewswire.com
GRAIL Reports Third Quarter 2026 Financial ResultsFDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif., Nov. 4, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.
19 days ago · zacks.com
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
20 days ago · prnewswire.com
GRAIL to Present at the UBS Global Healthcare ConferenceSUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m.
26 days ago · prnewswire.com
GRAIL to Announce Third Quarter 2026 Financial ResultsSUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.
1 month ago · wsj.com
First-Class Amenity Kits Have Become Holy Grail CollectiblesFor a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GRAL